Ignite Creation Date:
2025-12-25 @ 12:08 AM
Ignite Modification Date:
2025-12-25 @ 10:08 PM
Study NCT ID:
NCT04990258
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-24
First Post:
2021-06-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Sponsor:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-06
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-14
First Submit QC Date:
None
Study First Post Date:
2021-08-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-23
Last Update Post Date:
2024-01-24
Last Update Post Date Type:
ACTUAL